SEC Form 4 reporting owner

Hopkinson Craig C.

Hopkinson Craig C. has filed 34 Form 4 transactions reported between December 1, 2025 and September 1, 2026, as EVP R&D, Chief Medical Officer of Alkermes plc..

Name as filed: Hopkinson Craig C.

Open-market buys, 24 mo

None

reported

Open-market sales, 24 mo

$2.9M

11 lines

Companies

with Form 4 filings

Latest transaction

Sep 1, 2026

transaction date

Roles and reported holdings

ALKSAlkermes plc.
Dec 1, 2025 – Sep 1, 2026
EVP R&D, Chief Medical Officer
Held directly65,389 sh as of Sep 1, 2026 · Form 4
24 months: $2.9M sold

Transaction history

All 34 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

Date	Company	Type	Shares	Price	Value	Owned after	Filing
Sep 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$46.99	$423K@ $46.99	65,389	Form 4
Sep 1, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$24.59	$123K@ $24.59	74,389	Form 4
Aug 3, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$48.58	$437K@ $48.58	69,389	Form 4
Aug 3, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	4,896	$24.59	$120K@ $24.59	78,389	Form 4
Aug 3, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	104	$19.34	$2K@ $19.34	73,493	Form 4
Jul 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	700	$52.13	$36K@ $52.13	73,389	Form 4
Jul 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	8,300	$51.46	$427K@ $51.46	74,089	Form 4
Jul 1, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	82,389	Form 4
Jun 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$41.67	$375K@ $41.67	77,389	Form 4
Jun 1, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	86,389	Form 4
May 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$33.40	$301K@ $33.40	81,389	Form 4
May 1, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	90,389	Form 4
Apr 1, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$35.51	$320K@ $35.51	85,389	Form 4
Apr 1, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	94,389	Form 4
Mar 2, 2026	ALKSEVP R&D, Chief Medical Officer	Grant or awardCode A · direct	38,568	—	—	38,568	Form 4
Mar 2, 2026	ALKSEVP R&D, Chief Medical Officer	Grant or awardCode A · direct	83,037	—	—	83,037	Form 4
Mar 2, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	9,000	$29.72	$267K@ $29.72	89,389	Form 4
Mar 2, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	98,389	Form 4
Feb 26, 2026	ALKSEVP R&D, Chief Medical Officer	Shares withheld for tax or exercise priceCode F · direct	3,049	$30.73	$94K@ $30.73	93,389	Form 4
Feb 26, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	6,866	—	—	96,438	Form 4
Feb 23, 2026	ALKSEVP R&D, Chief Medical Officer	Shares withheld for tax or exercise priceCode F · direct	3,414	$32.19	$110K@ $32.19	89,572	Form 4
Feb 23, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	7,689	—	—	92,986	Form 4
Feb 19, 2026	ALKSEVP R&D, Chief Medical Officer	Shares withheld for tax or exercise priceCode F · direct	3,407	$32.00	$109K@ $32.00	85,297	Form 4
Feb 19, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	7,673	—	—	88,704	Form 4
Feb 18, 2026	ALKSEVP R&D, Chief Medical Officer	Shares withheld for tax or exercise priceCode F · direct	3,504	$32.02	$112K@ $32.02	81,031	Form 4
Feb 18, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	8,897	—	—	84,535	Form 4
Feb 5, 2026	ALKSEVP R&D, Chief Medical Officer	Shares withheld for tax or exercise priceCode F · direct	7,454	$33.55	$250K@ $33.55	75,638	Form 4
Feb 5, 2026	ALKSEVP R&D, Chief Medical Officer	Grant or awardCode A · direct	25,352	—	—	83,092	Form 4
Feb 2, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	4,000	$33.54	$134K@ $33.54	57,740	Form 4
Feb 2, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	66,740	Form 4
Jan 8, 2026	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	5,000	$19.34	$97K@ $19.34	66,740	Form 4
Jan 2, 2026	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	4,000	$28.00	$112K@ $28.00	61,740	Form 4
Dec 3, 2025	ALKSEVP R&D, Chief Medical Officer	Option exerciseCode M · direct	3,748	$19.34	$72K@ $19.34	69,488	Form 4
Dec 1, 2025	ALKSEVP R&D, Chief Medical Officer	Open-market saleCode S · direct	4,000	$29.30	$117K@ $29.30	65,740	Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.